Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 8 ·No. 12 ·2002-12-00 ·Pages 3643-5

Dalton WS

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/therapeutic use Arsenic Trioxide Arsenicals/therapeutic use Ascorbic Acid/therapeutic use Clinical Trials as Topic Drug Combinations Glutathione/metabolism Humans Mitochondria/drug effects Multiple Myeloma/drug therapy,pathology Oxides/therapeutic use Reactive Oxygen Species

Chemicals

Antineoplastic Agents Arsenicals Drug Combinations Oxides Reactive Oxygen Species Glutathione Ascorbic Acid Arsenic Trioxide

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Dalton William S

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

Article Info

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Abbr.

Clin Cancer Res

ISSN

1078-0432

Published

2002-12-00

Pages

3643-5

Language

English

Region

United States

NLM ID

9502500

Subset

Corrections

CommentIn

PMID: 12473574

External Links

PubMed source View journal details

Analysis Services

Contact

WeChat Official Account